Yes, and they only factor in a 5% chance of success of paxalisib for BCBM and essentially 0% chance of paxalisib in brain metastasis from all other cancers (i.e., what the Alliance trial is testing), so clearly an overly conservative figure IMO. Brain metastasis in general has 10x the revenue potential of the GBM indication.
Yes, and they only factor in a 5% chance of success of paxalisib...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)